Arthur Bergman

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 514 citations

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 498 citations

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Rajesh Krishna, Matt S. Anderson, Arthur Bergman et al. · The Lancet · 2007 · 276 citations

Metabolic Syndrome, Hypertension, Healthy Individuals +10

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers

Arthur Bergman, Catherine Stevens, Yanyan Zhou et al. · Clinical Therapeutics · 2006 · 265 citations

Pharmacological Study, Medicine, Healthy Male Volunteers +5

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 207 citations

Obesity, Metabolic Syndrome, Dgat2 Inhibitor +12